Thyroid Cancer Molecular Targets and Clinical Trials

Newswise — Identifying molecular targets for therapy represents a new paradigm for treating cancer, and physicians treating thyroid cancer are designing clinical trials to determine their efficacy. These research studies have recently been cited by the American Society of Clinical Oncology as among the most notable advances in cancer research published in 2008.

Steven I. Sherman, M.D. of the University of Texas M. D. Anderson Cancer Center will present "Differentiated Thyroid Carcinoma: Molecular-Targeted Therapy and Clinical Trials" at the American Thyroid Association's "National Thyroid Cancer Workshop II" to be held January 23-24 2009 at the Loews Miami Beach Hotel Miami, Florida. The session will be held Friday, January 23 at 5:00 p.m. in Americana 3, 2nd level.

The American Thyroid Association (ATA) is the lead organization in promoting thyroid health and understanding thyroid biology. The ATA values scientific inquiry, clinical excellence, public service, education, collaboration, and collegiality. ATA members are physicians and scientists who work to enhance the understanding of thyroid physiology and pathophysiology, improve diagnosis and treatment of thyroid diseases, and promote the education of physicians, patients, and the public about thyroid cancer. Thyroid diseases are the most disorders of the endocrine system, affecting almost 13 million Americans.